Skip to main content

Don’t invest unless you’re prepared to lose all your money.
These are high-risk investments and you are unlikely to be protected if something goes wrong.
Take 2 mins to learn more.

Summary of Life Sciences EIS

The Deepbridge Life Sciences EIS represents a compelling opportunity for private investors to participate in a selected portfolio of healthcare innovation, whilst taking advantage of the potential tax benefits available under the Enterprise Investment Scheme.

Participation in the Deepbridge Life Sciences EIS represents a unique opportunity for investors to access the investment expertise of a knowledgeable team in possession of over 200 years of cumulative experience of successfully mentoring entrepreneurs and building successful businesses.  Our aim is to provide investors with access to a portfolio of investee companies aligned with investors’ goals and ambitions. 

We also offer the Deepbridge Technology Growth EIS fund, for more details on this click here.

Investments in unquoted companies carry high risks and investors could lose all funds invested. Investors should not invest if capital is required in the near term. No established market exists for the trading of shares in private companies, making it difficult to sell shares. The value of tax reliefs depend on personal circumstances and may be subject to change in the future. The availability of tax reliefs depends on the Company invested in maintaining its qualifying status. Past performance is not a guide to the future performance of an investment, and investors are encouraged to take independent legal, tax and financial advice before considering an investment.

Investment Strategy

In order to provide investors with the best possible outcomes, the investment strategy of the Deepbridge Life Sciences EIS is to invest in a diversified portfolio of companies that participate in one of the following:

  • Biopharmaceuticals
  • Biotechnology
  • Medical Technology

Deepbridge takes an active role (not just a Board seat) to guide, mentor and counsel the investee management team. The provision of hands-on operational experience combined with financial expertise aims to mitigate the investment risk borne by the Investor, along with comprehensive due diligence on investee companies.

Key Features

Minimum Investment

£10,000

Compliance Status

Alternative Investment Fund

Sector

Life Sciences

Offer Size

Uncapped

HMRC Advance Assurance

Received before deployment into companies

Deployment

Usually monthly

Target Return

170p for every 100p invested

Target Timescale

4-5 years minimum

The Investment Team

Our life sciences investment team is dedicated to providing expert guidance and mentoring to our portfolio companies, ensuring they have an active and hands-on role in the development of the company. Further to this, our investment team is responsible for the extensive vetting and due diligence of prospective investee companies that are seeking funding.

Dr. Savvas Neophytou

Partner & Chief Investment Officer

Ben Carter

Investment Director, Head of Life Sciences

Dr. Andrew Round

Investment Director

Heather Hughes

Investment Co-Ordinator – Life Sciences

Deepbridge Charges

There are no management charges levied on the investor at the point of investment for subscriptions received by a financial adviser, resulting in up to 100% allocation of subscription. This ensures up to 100% tax efficiency for investors. Deepbridge fees are paid by the Investee Companies and are disclosed in the Information Memorandum. 

Please note that for direct investors (i.e. those that subscribe without a financial adviser involved), an additional charge of 2.5% including VAT will be deducted from the subscription to cover Deepbridge's costs associated with verifying the appropriateness of the Deepbridge EIS application.

Performance fee: an incentive fee of 20% of cash returned, in excess of 120% of the funds invested.

or clarification, once the Investor has received in cash the first 120 pence per 100 pence invested (ignoring any tax relief and representing a 20% Hurdle Rate on funds invested), any additional distributable cash will be paid as to 80% to the Investor and 20% to Deepbridge. 

Our Products

An opportunity to participate in a range of diverse portfolios, proactively managed by our sector experienced team. Tax advantages are potentially available via the Enterprise Investment Scheme and Seed Enterprise Investment Scheme. Please view our specific product pages for more information. Financial Advice is recommended.

An opportunity for investors to participate in a portfolio of seed-stage technology innovation companies, whilst taking advantage of the potential tax benefits available under the Seed Enterprise Investment Scheme.

An opportunity for investors participate in a portfolio of growth-focused technology companies, whilst taking advantage of the potential tax benefits available under the Enterprise Investment Scheme.

An opportunity for investors to participate in a portfolio of growth-focused healthcare innovation companies, whilst taking advantage of the potential tax benefits available under the Enterprise Investment Scheme.

An asset-backed opportunity for investors to target long-term capital growth by investing in renewable energy generating trading assets.

The Private Investor Network of Deepbridge Capital, enabling experienced investors to define their own portfolio of innovative Life Sciences and Technology companies.

Deepbridge Protect is an IHT mitigation service that seeks to help businesses obtain full IHT relief, through their membership of a trading Partnership participating in a qualifying trade, so as to qualify for Business Relief.